Low-Dose CT Lung Cancer Screening in Kuwait: Feasibility and Uptake
Official title: ALIA Kuwait: A Prospective Pilot Feasibility Study of Low-Dose Computed Tomography Screening for Lung Cancer in High-Risk Individuals in Kuwait
Run by Chest Diseases Hospital, Ministry of Health, Kuwait · NCT07766538 · Data updated 2026-11-12
This pilot tests whether offering low-dose CT lung cancer screening to high-risk adults in Kuwait is workable and acceptable, with about 500 participants completing a baseline scan.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years to 80 Years |
| Sex | All |
| Enrollment | 590 (estimated) |
| Sponsor | Chest Diseases Hospital, Ministry of Health, Kuwait Government |
| Locations | 1 site (Kuwait City) |
| Status | Recruiting |
| Started | September 1, 2026 |
| Main results expected | November 30, 2027 |
| Study ends | August 31, 2029 |
| Registry record updated | November 3, 2026 |
| Trial ID | NCT07766538 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are 50-80 years old with at least 20 pack-years of smoking (including all tobacco forms) and who can provide informed consent.
✕Probably not a fit
Individuals outside the age range, with lower smoking exposure, or with exclusion criteria such as active cancer surveillance or inability to lie flat for CT may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective, interventional feasibility study evaluates uptake and barriers to implementing low-dose CT screening for lung cancer in Kuwait. Eligible participants are adults aged 50-80 with at least 20 pack-years of smoking history, accounting for all tobacco products including shisha. Participants receive a baseline LDCT scan and may undergo two additional annual scans, with screening performed at the Chest Diseases Hospital and recruitment through MOH clinics. The primary goal is to establish a framework for a national screening program, while the co-primary analyses consider the baseline uptake and retention through 12 months. An extension cohort may enroll after the initial cohort closes, contributing to scan-based analyses but not to co-primary outcomes.
Why it matters
Potential benefit: If successful, the study could inform scalable LDCT screening implementation to reduce late-stage lung cancer by identifying high-risk individuals who benefit from early detection.
How similar studies have gone: Prior LDCT screening programs in other settings have shown feasibility and uptake benefits, though this Kuwait-specific feasibility study is among the first in the region.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 50 to 80 years * Smoking history of at least 20 pack-years, totalled across all smoked tobacco products (cigarettes, shisha/waterpipe, cigars, pipe and roll-your-own tobacco) using pre-specified equivalency conventions (1 shisha head-year = 1 pack-year; 1 cigar = 4 cigarettes; 1 pipe bowl = 2.5 cigarettes; roll-your-own tobacco 1 g = 1 cigarette). Electronic cigarettes, heated tobacco and smokeless products do not count. Current and former smokers are eligible regardless of time since quitting. * Able to provide informed consent Exclusion Criteria: * Previous diagnosis of lung cancer or any other cancer * Currently under surveillance for pulmonary nodules * A major comorbidity under active management (for example end-stage heart, lung or liver disease); people whose condition is under routine follow-up, such as COPD on inhaled treatment, bronchiectasis or interstitial lung disease, remain eligible * Unable to lie flat with arms raised above the head for CT scanning * Symptoms suggestive of lung cancer (persistent or worsening cough, haemoptysis, or unexplained weight loss of more than 15 lb (about 7 kg) in the past 3-12 months); symptomatic people are referred the same day on the normal diagnostic pathway * Chest CT for any reason in the past 12 months * Non-Kuwaiti residents who have lived in Kuwait for less than 2 years
Where it's running
-
Lung Cancer Screening Clinic, Chest Diseases Hospital
Kuwait City, Kuwait Recruiting
Study contacts
- Principal investigator: Sulaiman Khadadah, MD — Chest Diseases Hospital, Ministry of Health, Kuwait
- Study coordinator: Sulaiman Khadadah, MD
- Email: khadadas@tcd.ie
- Phone: +96555966111
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
3-D virtual resection to predict lung function after VATS anatomical lung surgery
The study will test whether a 3-D virtual resection from thin-slice CT scans can better predict lung function after VATS lobectomy or segmentectomy for people with non-small cell lung cancer.
-
Liquid biopsy pre-screen to reduce unnecessary low-dose CT for high-risk lung cancer
This will test a blood-based liquid biopsy to see if it can identify high-risk people who can safely skip or delay a low-dose CT scan for lung cancer.
-
Trop2- and EpCAM-targeted PET/CT to help distinguish non-small cell lung cancer
This project will test whether PET/CT scans that target Trop2 and EpCAM can show protein expression in tumors of people with suspected non-small cell lung cancer.
-
Mobile low-dose CT screening for lung cancer in younger adults
This study is testing if a mobile low-dose CT scan can help find lung cancer earlier in younger adults aged 40-54 who have a significant history of smoking.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
AI-assisted longitudinal CT to guide indeterminate lung nodules
This trial tests whether giving doctors an AI report that tracks nodules over serial CT scans helps reduce unnecessary benign lung resections in patients with indeterminate nodules.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.